The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results

What Was Tested

The paper reports a study of PT-141 (Bremelanotide) and Alpha-MSH, published as a randomized controlled trial.

Exit surveys and patient interviews were conducted to evaluate the impact of HSDD and bremelanotide treatment from the patient's perspective.

Why It Was Studied

A subset of up to 90 patients was invited to participate in the telephone interview (17 questions).

Patients who volunteered to participate remained blinded to study drug until the survey and interviews were completed.

Who Took Part

The study group was 250 participants.

PubMed tags the participants as women only.

Materials and Methods: Upon completion of the double-blind study but before participation in the open-label extension, up to 250 participants were recruited to complete the quantitative exit survey (17 questions).

How the Study Was Run

In design terms this was a randomized, double-blind, open-label and placebo-controlled study.

Because people in this PT-141 (Bremelanotide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind PT-141 (Bremelanotide) study, the assignments were hidden from both participants and investigators until the end.

Nothing was hidden in this open-label PT-141 (Bremelanotide) study: the participants and staff both knew the treatment.

A placebo (an inactive look-alike) gave the PT-141 (Bremelanotide) group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Libido, Patient Outcome Assessment, Peptides, Cyclic, Quality of Life, Sexual Dysfunctions, Psychological and alpha-MSH.

The authors tagged it with the keywords bremelanotide, exit survey, female sexual dysfunction, hypoactive sexual desire disorder and premenopausal.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of PT-141 (Bremelanotide) and Alpha-MSH in 250 participants.

The publication is from 2021 (Journal of women's health (2002)), a journal based in United States.

More context: the PT-141 (Bremelanotide) compound page and the Alpha-MSH compound page, all human trials.